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Abstract		
Purpose:	To	investigate	the	effect	of	different	DEAF1	variants	on	the	phenotype	of	
patients	with	autosomal	dominant	and	recessive	inheritance	patterns	and	on	DEAF1	
activity	in	vitro.	Methods:	We	assembled	a	cohort	of	23	patients	with	de	novo	and	
biallelic	DEAF1	variants,	described	the	genotype‐phenotype	correlation	and	
investigated	the	differential	effect	of	de	novo	and	recessive	variants	on	transcription	
assays	using	DEAF1	and	Eif4g3	promoter	luciferase	constructs.	Results:	The	
proportion	of	the	most	prevalent	phenotypic	features,	including	intellectual	
disability,	speech	delay,	motor	delay,	autism,	sleep	disturbances,	and	a	high	pain	
threshold,	were	not	significantly	different	in	patients	with	biallelic	and	pathogenic	
de	novo	DEAF1	variants.	However,	microcephaly	was	exclusively	observed	in	
patients	with	recessive	variants	(p<0.0001).		Conclusion:	We	propose	that	different	
variants	in	the	DEAF1	gene	result	in	a	phenotypic	spectrum	centered	around	
neurodevelopmental	delay.	While	a	pathogenic	de	novo	dominant	variant	would	also	
incapacitate	the	product	of	the	wild‐type	allele	and	result	in	a	dominant‐negative	
effect,	a	combination	of	two	recessive	variants	would	result	in	a	partial	loss‐of‐
function.	Since	the	clinical	picture	can	be	non‐specific,	detailed	phenotype	
information,	segregation,	and	functional	analysis	are	fundamental	to	determine	the	
pathogenicity	of	novel	variants	and	to	improve	the	care	of	these	patients.		
	
Keywords:	DEAF1,	neurodevelopmental	disorder,	intellectual	disability,	genotype,	
phenotype	
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Introduction	
	 DEAF1	(MIM*602635;	NM_021008.3)	encodes	the	deformed	epidermal	
autoregulatory	factor‐1	homolog	(DEAF1),	a	transcription	factor	that	is	highly	
expressed	in	the	central	nervous	system,	in	particular	during	early	embryogenesis.1	
DEAF1	regulates	the	expression	of	various	genes2	as	both	a	transcriptional	activator	
and	repressor.3‐6	It	contains	several	functional	domains	including	a	centrally	located	
SAND	(Sp‐100,	AIRE,	NucP41/75,	and	DEAF1) domain,	a	zinc	finger	motif	(ZnF),	a	
nuclear	localization	signal	(NLS),	a	nuclear	export	signal	(NES),	and	an	MYND	
(myeloid	translocation	protein	8,	Nervy,	and	DEAF1)	domain	(Figure	1).6,7	The	
region	encompassing	the	SAND	domain	constitutes	a	DNA	binding	domain,	which	
binds	to	TTCG	motifs.6	The	SAND	and	MYND	domains	are	also	involved	in	protein‐
protein	interactions.6‐9	The	presence	of	a	NLS	and	NES	indicates	that	DEAF‐1	may	be	
regulated	by	nuclear/cytoplasmic	shuttling.7	Biallelic	disruption	of	Deaf1	in	mice	
results	in	neural‐tube	defects10,	and	biallelic	Drosophila	Deaf1	loss‐of‐function	
mutants	show	early	embryonic	arrest11.	
Pathogenic	variants	in	the	DEAF1	gene	have	been	reported	to	lead	to	two	
clinically	distinct	intellectual	disability	(ID)	syndromes:	autosomal	dominant	mental	
retardation‐24	(MRD24;	MIM#615828)	caused	by	de	novo	variants,1,12‐17	and	the	
recessively	inherited	dyskinesia,	seizures,	and	intellectual	developmental	disorder	
syndrome	(DYSEIDD;	MIM#617171)16,18‐20.	These	two	syndromes	are	collectively	
described	as	DEAF1‐associated	neurodevelopmental	disorders	(DAND).	To	date,	
nine	different	de	novo	pathogenic	variants	have	been	described	in	ten	individuals,	
who	manifested	moderate	to	severe	ID	with	severely	affected	expressive	speech	and	
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mild	motor	delay.1,12‐17	Epilepsy	was	described	in	half	of	the	individuals.16	
Behavioral	problems	consisted	of	hyperactive,	compulsive	and/or	aggressive	
behavior,	fascination	with	water,	and	striking	mood	swings.1,14‐16	Other	
characteristics	were	autism,	recurrent	infections,	a	high	pain	threshold,	and	an	
abnormal	walking	pattern.1,14‐16	Body	measurements	were	normal,	facial	
dysmorphisms	were	only	mild,	and	no	other	major	congenital	anomalies	were	
observed.1	All	but	one	of	the	de	novo	pathogenic	DEAF1	variants	occurred	in	the	
SAND	domain,	including	seven	missense	variants	and	one	splice	site	variant.1,12‐17	
One	in‐frame	deletion	of	three	base	pairs	was	reported	in	the	NLS	domain.16	These	
de	novo	pathogenic	DEAF1	variants	impair	the	DEAF1	transcriptional	activity,	DNA‐
binding,	and/or	alter	subcellular	localization.1,16	Since	heterozygous	DEAF1	
deletions21	do	not	cause	DAND,	de	novo	pathogenic	variants	have	been	proposed	to	
lead	to	a	dominant‐negative	effect.1	
Two	kindreds	with	patients	with	homozygous	DYSEIDD	pathogenic	DEAF1	
variants	were	previously	reported,	a	missense	change	and	a	non‐canonical	splice	
site	pathogenic	variant.16,18‐20	In	total,	seven	patients	homozygous	for	either	of	these	
variants	presented	with	ID,	microcephaly,	and	hypotonia,	were	described.16,18‐20	
Seizures	and	white	matter	abnormalities	resulting	in	dyskinesia	were	reported	in	
four	out	of	the	six	patients	for	which	these	features	were	investigated.18‐20	The	
missense	variant	was	present	in	the	SAND	domain	as	well,	whereas	the	splice	site	
variant	resulted	in	exon	skipping	and	reduced	the	normal	full‐length	mRNA	copy	
number	in	the	patients	to	5%	of	the	wild‐type	level,19	suggesting	that	the	recessive	
phenotype	resulted	from	a	partial	loss‐of‐function	of	DEAF1.	
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In	order	to	investigate	the	effect	of	different	DEAF1	variants	on	the	
phenotype	of	patients	with	autosomal	dominant	and	recessive	inheritance	patterns,	
we	have	assembled	a	cohort	of	23	patients	not	reported	before	with	de	novo	and	
biallelic	DEAF1	variants.	We	describe	the	genotype‐phenotype	correlation	and	
investigate	the	differential	effect	of	de	novo	and	recessive	variants	on	DEAF1	activity	
in	vitro.	 	
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Patients	&	Methods		
Identification	of	individuals	
Patients	were	referred	by	physicians	working	in	intellectual	disability	support	
services	and	by	clinical	geneticists.	Written	informed	consent	was	obtained	for	all	
individuals	involved.	This	study	adhered	to	the	World	Health	Association	
Declaration	of	Helsinki	(2013)	and	was	approved	by	the	institutional	review	board	
Commissie	Mensgebonden	Onderzoek	Regio	Arnhem‐Nijmegen.	Genomic	DNA	was	
isolated	from	peripheral	blood	samples	following	standard	procedures.22	Exome	
enrichment,	high‐throughput	sequencing,	and	subsequent	de	novo	analysis	was	
performed	by	established	procedures.23	Copy	number	variant	analysis	was	
performed	on	exome	data	by	using	CoNIFER1,24	as	described	before.25		
	
Plasmid	constructs	
DEAF1	mammalian	expression	and	DEAF1	and	Eif4g3	promoter	luciferase	plasmids	
have	been	previously	described.1	Site‐directed	mutagenesis	was	used	to	introduce	
the	specific	amino	acid	substitutions	into	the	DEAF1	expression	plasmids,	derived	
from	the	human	DEAF1	cDNA	(GenBank	accession	number	AF049459).	Variants	
resulting	in	the	indicated	human	amino	acid	substitutions	were	generated	by	PCR	as	
previously	described.1	
	
Transcription	assays	
Luciferase	assays	using	DEAF1	and	Eif4g3	promoter	luciferase	constructs	have	been	
previously	described.1	Briefly,	HEK293T	cells	in	24‐well	plates	were	transfected	
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with	125	ng	pcDNA3	(control)	or	DEAF1	(WT	or	DEAF1	variants)	expression	
plasmids	with	375	ng	promoter‐luciferase	and	1.25	ng	RSV‐Renilla	luciferase	
constructs	using	the	calcium	phosphate	technique	for	18	h.	Luciferase	assays	were	
performed	24	hours	later	using	the	Dual‐Luciferase	Reporter	Assay	System	
(Promega,	Madison,	WI	USA).	
	
DEAF1	EBV‐LCL	RNA	analysis	
Epstein	Barr	virus‐transformed	lymphoblastoid	cell	line	(EBV‐LCL)	cells	(8x106	
cells)	were	grown	in	20	mL	RPMI	supplemented	with	15%	fetal	bovine	serum,	
penicillin,	and	streptomycin.	Twenty‐four	hours	later	10	mL	was	removed	to	a	new	
flask	and	cells	were	treated	with	vehicle	(water)	or	cycloheximide	(50	ug/mL)	for	6	
hours.	RNA	was	isolated	from	EBV‐LCL	cells	using	Trizol	reagent	and	1.0	ug	of	RNA	
was	reverse	transcribed.	PCR	was	performed	using	cDNA	and	primers	to	amplify	
specific	regions	of	DEAF1	cDNA	for	downstream	restriction	digests	or	subcloning	
and	DNA	sequencing.	Quantitative	PCR	was	performed	using	DEAF1	(1617dup)	and	
GAPDH	primers26	and	data	were	normalized	using	the	2(‐ΔΔCt)	method.27		
	
Immunoprecipitation	and	Western	Blot	
EBV‐LCL	were	lysed	in	lysis	buffer	containing	150	mM	sodium	chloride,	50	mM	Tris	
(pH=7.5),	1.0%	TritonX‐100,	1.0	mM	EDTA,	1.0	mM	sodium	fluoride,	0.2	mM	sodium	
orthovanadate,	aprotinin	(10	g/mL),	leupeptin	(10	g/mL)	and	pepstatin	(10	
g/mL)	and	lysates	were	incubated	with	rabbit	DEAF1	antibodies8	or	preimmune	
serum	bound	to	protein	G	magnetic	beads	overnight	at	4oC.	Beads	were	washed	and	
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proteins	were	eluted	in	Laemmli	sample	buffer.	Transfected	HEK293t	cells	were	
lysed	in	lysis	buffer.	Proteins	were	separated	on	SDS‐PAGE	gels	and	transferred	to	
polyvinylidene	fluoride	membranes.	Immunoblot	analysis	was	performed	with	a	
different	rabbit	anti‐DEAF1	antibody	for	EBV‐LCL	immunoprecipitation	
experiments	or	rabbit	anti‐DEAF1	and	mouse	anti‐bACTIN	(Abcam,	Cambridge,	MA	
USA)	for	transfected	HEK293t	experiments.		
	
Genotype‐phenotype	correlations	
Fisher’s	Exact	Test,	using	a	two‐sided	p‐value,	was	carried	out	to	compare	
proportions	of	clinical	features	between	groups	of	patients	with	de	novo	and	biallelic	
DEAF1	variants.	After	conducting	Bonferroni	correction,	a	p‐value	of	<0.0025	was	
considered	significant.	
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Results	
De	novo	variants	in	the	SAND	domain	of	DEAF1	impair	transcriptional	activity	
We	identified	14	novel	and	two	previously	published	de	novo	DEAF1	variants	
in	a	total	of	18	patients	by	exome	sequencing	(n=16),	genome	sequencing	(n=1),	
autism	gene	panel	analysis	(n=1)	performed	in	17	medical	centres	from	all	over	the	
world	(Figure	1;	Table	S1).	These	variants	included	14	missense	variants,	one	in‐
frame	deletion	that	resulted	in	a	single	amino	acid	change,	and	one	splice	site	
variant,	c.664+1G>T.	To	determine	if	the	c.664+1G>T	variant	resulted	in	
alternatively	spliced	DEAF1	mRNA	transcripts,	PCR	was	used	to	amplify	regions	
containing	exons	2‐5	using	Epstein	Barr	virus‐transformed	lymphoblastoid	cell	line	
(EBV‐LCL)	mRNA	from	individual	AD/8.	DNA	sequencing	indicated	the	variant	
causes	skipping	of	exon	4,	which	results	in	an	in‐frame	deletion	of	49	amino	acid	
residues	in	the	SAND	domain	p.(Pro174_Gly222del)	(Figure	2).	Compared	to	control	
EBV‐LCL,	a	truncated	DEAF1	protein,	as	well	as	full	length	DEAF1,	were	observed	in	
patient	AD/8	EBV‐LCL	lysate	and	corresponded	to	a	similar	molecular	weight	
protein	using	lysates	from	cells	transfected	with	WT	or	p.(Pro174_Gly222del)	
plasmid	DNA.	The	novel	variant	p.(Ala276Pro)	was	found	in	two	unrelated	
individuals	from	this	study.	The	previously	reported	de	novo	variants	p.(Gly212Ser)	
and	p.(Gln264Pro)1,13,16	were	identified	in	our	cohort	in	two	and	one	families,	
respectively.	The	p.(Gly212Ser)	variant	was	identified	in	two	out	of	the	247	reads	in	
peripheral	blood	cells	of	the	patient’s	unaffected	father.	The	variant	was	not	
detected	by	Sanger	sequencing,	suggesting	that	he	is	likely	a	mosaic	for	this	variant.		
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Fifteen	of	the	sixteen	de	novo	variants	are	located	in	the	SAND	or	adjacent	
ZnF	domain;	the	p.(Pro293Leu)	variant	is	between	the	ZnF	and	NLS	(Figure	1c).	All	
missense	variants	were	predicted	by	SIFT28	and	Polyphen‐229	to	be	disease‐causing	
and	had	a	CADD	score	>20.0.30	None	of	the	novel	de	novo	variants	were	found	in	
gnomAD	(Genome	Aggregation	Database).31	Multispecies	alignment	showed	that	all	
mutated	amino	acids	are	highly	conserved	across	species	(Figure	S1).	
DEAF1	binds	and	represses	its	own	promoter	activity.32	DEAF1	promoter	
transcriptional	repression	activity	was	analyzed	for	de	novo	variants.	All	variants	
lost	transcriptional	repression	activity	as	compared	to	wild	type	DEAF1,	although	
p.(Pro293Leu)	retained	some	repression	activity	(Figure	3A).	DEAF1	also	increases	
the	transcriptional	activity	of	the	mouse	Eif4g3	promoter5	and	de	novo	DEAF1	
variants	have	previously	been	shown	to	suppress	activation	of	this	promoter.1	In	12	
out	of	our	14	variants,	an	approximate	10‐fold	suppression	of	transcriptional	
activity	relative	to	basal	expression	levels	was	demonstrated.	No	activation	or	
reduction	in	promoter	activity	was	observed	for	p.(Ser236Gly)	relative	to	basal	
activity,	and	p.(Pro293Leu)	increased	promoter	activity	(Figure	3B).	
	
Biallelic	variants	in	DEAF1	result	in	no	significant	effect	in	transcriptional	
assays		
Six	novel	biallelic	DEAF1	variants	were	found	in	compound	heterozygosity	in	
three	unrelated	individuals	and	one	novel	homozygous	variant	was	identified	in	two	
siblings	of	a	consanguineous	family	by	using	exome	sequencing	(Figure	1d;	Table	
S2).	These	variants	were	scattered	throughout	DEAF1.	In	two	families,	compound	
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heterozygous	variants,	p.(Trp234*)	and	p.(Glu239Gly),	or	a	homozygous	variant,	
p.(Arg224Gln),	were	found	in	the	SAND	domain.	The	compound	heterozygous	
missense	variant	p.(Glu239Gly)	is	not	reported	in	gnomAD	and	is		predicted	by	SIFT	
to	be	deleterious,	by	Polyphen‐2	to	be	probably	damaging,	and	had	a	CADD	score	25.	
The	homozygous	substitution	p.(Arg224Gln)	located	in	the	SAND	domain	is	present	
only	once	heterozygously	in	gnomAD	(frequency	of	4.065e‐6),	was	predicted	by	
SIFT	to	be	tolerated,	by	Polyphen‐2	to	be	disease‐causing,	and	had	a	CADD	score	31.	
In	the	other	two	families,	a	single	base	pair	duplication	or	deletion	resulting	in	
frameshift	near	to	the	5’	of	DEAF1,	p.(Arg44Glyfs*25),	or	in	the	middle	of	the	DEAF1	
gene,	p.(Asp369Alafs*51),	both	located	outside	a	domain,	occurred	in	combination	
with	a	variant	in	the	MYND	domain,	respectively	an	in‐frame	deletion,	p.(Phe527del)	
or	an	insertion	resulting	in	a	frameshift,	p.(Cys540Metfs*18).	Three	of	these	
variants,	p.(Arg44Glyfs*25),	p.(Trp234*),	and	p.(Asp369Alafs*51)	are	expected	to	
lead	to	nonsense‐mediated	decay	(NMD)	of	their	respective	transcripts.		
	 DEAF1	mRNA	expression	analysis	was	performed	using	EBV‐LCL	from	
patient	AR/1,	who	carried	c.1617dup,	p.(Cys540Metfs*18),	and	c.1104_1105dup,	
p.(Asp369Alafs*51)	in	compound	heterozygosity,	and	from	parents	carrying	either	
the	c.1617dup	or	c.1104_1105dup.	To	differentiate	the	expression	of	DEAF1	
transcripts	from	each	allele,	two	different	PCR	amplicons	were	generated	that	
contain	either	c.1617dup	or	c.1104_1105dup	variant	from	patient	and	parent	EBV‐
LCL	treated	with	vehicle	or	cycloheximide	(CHX),	an	inhibitor	of	NMD.	The	
c.1617dup	eliminates	an	endogenous	NdeI	site	and	the	c.1104_1105dup	generates	a	
new	HhaI	site.	Restriction	endonuclease	digestion	analysis	indicated	that	both	
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c.1617dup	or	c.1104_1105dup	containing	mRNA	transcripts	were	present	in	patient	
and	parent	cDNA.	The	c.1104_1105dup	transcript	seemed	to	be	present	in	a	lower	
amount	in	cells	not	treated	with	CHX	as	compared	to	those	treated	with	CHX.	As	CHX	
is	an	inhibitor	of	NMD,	this	suggests	that	this	transcript	is	subject	to	NMD	(Figure	
S2).	DEAF1	immunoprecipitaions	were	performed	on	EBV‐LCL	lysates	from	patient	
and	parents.		Compared	to	parent	EBV‐LCL,	no	full	length	or	p.(Cys540Metfs*18)	
~80	kDa	DEAF1	protein	was	observed	in	patient	lysate.		A	faint	truncated	~60kDa	
band	consistent	with	the	p.(Asp369Alafs*51)	DEAF1	protein	was	observed	in	
patient	and	parent	c.1104_1105dup.		Quantitative	PCR	(qPCR)	showed	that	DEAF1	
mRNA	expression	in	untreated	EBV‐LCL	of	the	patient	AR/1	
(c.1104_1105dup/c.1617dup	variants)	was	30%	of	normal	EBV‐LCL	expression	
levels	(p<0.05),	Figure	S3).	CHX	treatment	significantly	increased	DEAF1	mRNA	
expression	relative	to	vehicle	treated	cells	in	c.1104_1105dup/c.1617dup	patient	as	
well	as	the	parent	carrying	the	c.1104_1105dup	supporting	that	the	
c.1104_1105dup	containing	transcript	is	targeted	by	NMD	
The	effects	of	the	biallelic	variants	on	DEAF1	transcriptional	activity,	protein	
expression,	and	cellular	localization	were	also	determined.	Compared	to	WT	DEAF1,	
no	change	in	transcriptional	repression	activity	was	observed	for	the	biallelic	
variants,	except	for	p.(Trp234*)	(Figure	3C).	No	significant	change	in	transcriptional	
activation	of	the	Eif4g3	promoter	was	observed.	(Figure	3D).	Interestingly,	
p.(Arg44Glyfs*25),	which	should	result	in	a	severely	truncated	DEAF1	protein	that	
lacks	most	of	the	DEAF1	protein	domains	including	the	SAND	domain,	retained	
transcriptional	activity.		Western	blots	were	performed	using	lysates	from	HEK293t	
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transfected	with	WT	or	DEAF1	biallelic	variants.	A	faint	~70	kDa	protein	was	
observed	for	p.(Arg44Glyfs*25)	(Figure	S4).	This	might	be	the	result	of	the	use	of	a	
translational	start	at	a	downstream	in‐frame	AUG	start	codon	located	at	codon	69.	
The	p.(Arg44Glyfs*25)	variant	results	in	a	stop	codon	5’	adjacent	to	methionine	69	
of	DEAF1.	The	p.(Trp234*)	and	p.(Asp369Alafs*51)	variants	resulted	in	truncated	
DEAF1	proteins	approximately	30	and	60	kDa	in	size,	respectively.	The	
p.(Cys540Metfs*18)	variant	resulted	in	a	slightly	lower	molecular	weight	protein.	As	
expected	p.(Arg224Gln),	p.(Glu239Gly),	and	p.(Phe527del)	variants	had	the	same	
apparent	molecular	weight	as	WT	DEAF1.		Immunofluorescent	staining	was	used	to	
determine	the	subcellular	localization	of	the	biallelic	DEAF1	variants	in	transfected	
cells.	Unlike	WT	DEAF1,	which	localized	to	the	nucleus,	p.(Trp234*)	was	found	
throughout	the	cell	(Figure	S5).		The	other	biallelic	variants	localized	to	the	nucleus.		
	
De	novo	DEAF1	variants	result	in	a	non‐specific	phenotype	comprising	ID,	
speech	delay,	motor	delay,	sleep	disturbance,	autism,	and	a	high	pain	threshold		
Fourteen	male	and	three	female	individuals	with	a	de	novo	DEAF1	variant	(median	
age:	7.5	years;	age	range:	2.5	years	–	38	years),	were	clinically	characterized	(Table	
1;	Table	S3).	All	were	born	from	healthy	unrelated	non‐consanguineous	families.		
This	cohort	consisted	of	eleven	children,	six	of	which	were	preschool	children,	three	
were	adolescents	and	three	were	adults.	One	individual	was	excluded	from	
genotype‐phenotype	analysis,	as	he	had	the	variant	p.(Pro293Leu),	which	was	not	
located	in	the	SAND	domain	and	did	not	result	in	suppression,	but	rather	an	
increase	of	Eif4g3	promoter	activity.	
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Developmental	delay	(DD)/ID	was	present	in	all	patients	(17/17;	100%)	and	
was	typically	moderate‐severe	or	severe	DD/ID	(Table	S4).	Motor	delay,	present	in	
most	of	the	patients	(12/17;	71%),	was	usually	mild.	Language	development	was	
severely	delayed	in	all	patients,	except	for	one	patient	with	the	variant	
p.(Leu214Val)	(16/17;	94%).	Seven	patients	had	absent	speech	and	nine	had	limited	
speech.	Of	note,	nonverbal	patients	were	said	to	have	used	a	few	words	before	
losing	the	ability	to	produce	speech.	Developmental	regression	was	described	in	half	
of	the	individuals,	mostly	corresponding	to	loss	of	the	ability	of	communicating	
verbally.	Although	in	most	individuals	expressive	language	was	severely	impaired,	
receptive	language	was	perceived,	particularly	by	caregivers,	as	better	than	
expressive.	Furthermore,	patients	(15/15;	100%)	were	able	to	communicate	simple	
needs	nonverbally,	for	instance	taking	the	caregivers’	hand	to	point	or	lead	to	the	
item(s)	of	interest,	using	gestures	and	sign	language,	producing	sounds	
accompanied	(or	not)	by	gestures	(e.g.	to	express	emotions,	as	annoyance),	or	using	
picture	exchange	communication	system,	picture	prompts,	a	tablet,	or	a	touch‐based	
speech‐generating	device.		
Autism	spectrum	disorder	occurred	in	all	patients	(16/16;	100%).	In	the	
majority,	poor	eye	contact	(12/16;	75%),	fascinations	(15/17;	88%),	particularly	a	
compulsive	interest	in	water,	and	sudden	mood	swings	(16/17;	94%)	were	
concomitantly	observed.		Mood	swings	were	characterized	by	exaggeration	of	
emotional	affects,	with	paroxysmal	bursts	of	laughter	and	context‐inappropriate	
happy	disposition	alternating	with	aggressive	behavior	or	depressive	feelings.	
Aggressive	behavior	(12/16;	75%)	manifested	both	as	hetero‐aggression	and	auto‐
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aggression	(e.g.	self‐mutilation,	head‐banging,	self‐biting).	Other	behavioral	
problems	(13/15;	87%)	included	pica,	impulsivity/hyperactive	behavior,	and	
obsessive	traits.		
Epilepsy	was	also	observed	in	the	majority	of	patients	(10/14;	71%).	Median	
age	at	diagnosis	was	three	years,	although	age	of	onset	varied	from	two	days	old	to	
16	years	old	(Table	S5).	Seizures	were	usually	generalized	and	frequently	difficult	to	
treat	or	intractable	(9/10;	90%).	Anti‐epileptic	drugs	(AED)	were	able	to	reduce	
seizures	in	five	patients,	while	in	four	other	patients	seizures	were	refractory	to	
treatment.	Of	note,	seizures	were	noticed	to	adversely	influence	speech.	
Sleep	dysfunction	was	frequent	and	severe	(15/17;	88%).	It	consisted	of	
difficulty	falling	asleep	(sleep	onset	insomnia)	and	awaking	frequently	
(maintenance	insomnia).	Patients	were	reported	to	be	very	disruptive	when	waking	
during	the	night.	In	some	patients,	sleeping	problems	were	treated	with	some	
benefit	using	medication,	such	as	melatonin.	
Other	neurologic	abnormalities	included	a	remarkably	high	pain	threshold	
(14/16;	88%),	hypotonia	(10/16;	63%)	and	gait	difficulties,	comprising	of	gait	
ataxia	(4/16;	25%)	or	an	ataxic	looking	gait	(12/17;	71%),	as	broad‐based	and	
imbalanced	gait,	or	a	tip‐toe	gait.	Brain	abnormalities	as	indicated	by	brain	MRI	
were	present	in	less	than	a	third	of	the	patients	(4/13;	31%),	but	no	common	
pattern	of	brain	malformations	could	be	distinguished.	Movement	disorder,	in	
particular	dystonia,	was	only	reported	in	one	individual.	
Non‐neurodevelopmental	issues	included	recurrent	infections	that	occurred	
in	more	than	half	of	patients	(10/16;	63%),	mostly	in	infancy	or	childhood.	They	
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included	predominantly	chronic	ear	infections,	sinusitis,	or	upper	respiratory	tract	
infections.	In	addition,	gastrointestinal	abnormalities	were	common	(12/16;	75%)	
and	included	feeding	difficulties,	gastroesophageal	reflux	disease,	constipation,	and	
diarrhea.	Craniofacial	dysmorphisms	were	mild	(Figure	1e)	and	macrocephaly	was	
observed	in	approximately	one	quarter	of	individuals	(4/17;	24%).		Growth	was	
usually	within	the	norm	for	age	and	gender.		
	
Biallelic	DEAF1	variants	result	in	microcephaly	
Microcephaly	(3/5;	60%)	was	exclusively	observed	in	patients	with	recessive	
variants.	All	patients	with	biallelic	DEAF1	variants	manifested	ID	and	developmental	
regression,	except	for	one	(Tables	S6	and	S7).	All	parents	were	healthy.	Remarkably,	
although	the	patient	with	variants	p.(Asp369Alafs*51)	and	p.(Cys540Metfs*18)	in	
compound	heterozygosity	never	learned	to	walk	and	had	absent	speech,	similarly	to	
other	patients	with	biallelic	DEAF1	variants,	he	completed	various	exams	from	the	
first	grade	of	secondary	school,	suggesting	he	has	a	normal	cognitive	function,	
although	this	was	not	formally	tested.	Additionally,	he	used	non‐verbal	
communication	aids	(supportive	typing)	that	revealed	good	receptive	language.	
Behavioral	problems	occurred	in	all	patients	and	ranged	from	poor	eye	contact	
(4/5;	80%)	to	autism	(1/4;	25%)	and	aggressive	behavior	(2/5;	40%).	Frequent	
neurologic	abnormalities	included	epilepsy	(4/5;	80%)	(Tables	S5),	sleep	
disturbance	(5/5;	100%),	and	brain	abnormalities	(4/5;	80%),	such	as	
ventriculomegaly	with	or	without	hydrocephalus,	corpus	callosum	hypoplasia	or	
white	matter	abnormalities.	Movement	disorder	(2/4;	50%)	included	dystonia	and	
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stereotypies.	Common	extra‐neurologic	features	included	feeding	difficulties	(3/5;	
60%)	and	constipation	(5/5;	100%).	Lastly,	facial	dysmorphisms	were	minor	and	
non‐specific	(Figure	1e).	
	
De	novo	and	biallelic	variants	result	in	a	similar	phenotype	except	for	
microcephaly		
The	proportion	of	the	most	prevalent	phenotypic	features,	including	ID,	
speech	delay,	motor	delay,	autism,	sleep	disturbances,	and	a	high	pain	threshold,	
was	not	significantly	different	in	patients	with	biallelic	and	pathogenic	de	novo	
DEAF1	variants,	when	considering	all	patients	included	in	this	study	and	previously	
described	individuals	(Table	1).	Interfamilial	phenotypic	variability	was	observed	
among	patients	with	the	same	de	novo	variant	(e.g.	some	patients	developed	
seizures,	while	others	did	not).	Microcephaly,	however,	was	observed	exclusively	in	
patients	with	recessive	variants	(p<0.0001).			 	
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Discussion	
In	this	study,	we	expanded	the	clinical	consequences	of	variants	implicated	in	
DEAF1‐associated	neurodevelopmental	disorders	(DAND)	by	describing	the	
phenotype	of	17	patients	with	a	de	novo	pathogenic	variant	and	five	patients	with	
biallelic	variants	in	the	DEAF1	gene.	We	determined	that	the	de	novo	variants	
impaired	DEAF1	transcriptional	repression	activity	and	fifteen	of	the	seventeen	
variants	reversed	DEAF1‐mediated	transcriptional	activation	at	the	Eif4g3	
promoter.	Apart	from	the	p(Trp234*)	variant,	the	other	six	novel	recessive	DEAF1	
variants	demonstrated	no	change	in	transcriptional	activity.			
We	identified	missense	variants	in	the	SAND	domain,	both	de	novo	and	
recessive.	Only	de	novo	variants,	however,	altered	DEAF1	and	Eif4g3	promoter	
activity.	This	is	in	line	with	previous	data	implying	a	dominant‐negative	effect	of	
these	variants.1	So	far,	no	de	novo	nonsense	or	frameshift	variants	resulting	in	
disease	have	been	identified.	De	novo	variants	clustered	in	very	close	proximity	
within	the	SAND	domain.	Moreover,	variants	have	been	found	recurrently	affecting	
the	same	residues,	namely	p.Gly212,	p.Leu214,	p.Lys216,	p.Ile228,	p.Arg254,	
p.Gln264	and	p.Ala276.1,12‐20	Additionally,	the	canonical	donor	splice	site	3’	of	c.664	
was	also	found	to	be	repeatedly	affected.17	We	show	in	our	study	that	c.664+1G>T	
causes	skipping	of	exon	4,	producing	an	in‐frame	deletion	in	the	SAND	domain	that	
results	in	abnormal	transcriptional	activity	mimicking	the	effect	of	other	missense	
variants	on	DEAF1	protein	activity.		
Missense	biallelic	variants	in	the	SAND	domain	do	not	impair	the	function	of	
this	domain	as	evidenced	by	the	normal	transcriptional	activity	of	the	mutant	
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protein	in	our	assays.	This	is	especially	remarkable	for	the	novel	homozygous	
variant	p.(Arg224Gln),	as	the	previously	reported	de	novo	p.(Arg224Trp)	variant	
was	shown	to	result	in	loss	of	transcriptional	repression	of	the	DEAF1	promoter,	
and	was	unable	to	activate	the	Eif4g3	promoter.1	We	hypothesize	that	the	
p.(Arg224Gln)	variant	affects	normal	protein	folding	of	DEAF1	because	arginine,	an	
amino	acid	with	an	electrically	charged	side	chain,	is	replaced	by	an	amino	acid	with	
a	polar	uncharged	chain. This	is	also	the	case	for	the	recessive	p.(Arg226Trp)	
variant,	also	located	in	the	SAND	domain.16,18,20	Similarly,	the	compound	
heterozygous	variant	p.(Glu239Gly),	which	results	in	a	protein	with	an	apparently	
normal	length,	may	have	also	an	effect	on	the	normal	protein	folding,	due	to	the	
substitution	of	the	electrically	charged	side	chain	of	a	glutamate	for	a	glycine	with	a	
small	non‐polar	side	chain.	It	is	possible	the	DEAF1	variants	could	influence	other	
aspects	of	DEAF1	function	or	activity	that	may	not	be	detected	by	the	cell‐based	
functional	assays	used	in	this	study.	Thus,	we	predict	that	these	variants	constitute	a	
classical,	but	incomplete	loss‐of‐function	(hypomorph).		
Loss‐of‐function	recessive	variants	in	DEAF1	consist	of	p.(Arg44Glyfs*25),	
p.(Trp234*),	p.(Asp369Alafs*51),	and	p.(Cys540Metfs*18).	Only	p.(Trp234*)	
affected	transcriptional	repression	activity.	This	variant	likely	results	in	a	truncated	
protein	lacking	most	of	the	SAND	domain.		Our	results	suggest	that	the	DEAF1	
transcript	containing	the	p.(Arg44Glyfs*25)	variant	can	be	transcribed	using	an	
alternative	start	codon	resulting	in	a	N‐terminal	deletion	of	69	amino	acid	residues,	
and	thus	in	an	intact	SAND	domain.	Accordingly,	these	data	indicate	the	MYND	
domain	is	not	essential	for	DEAF1	transcriptional	repression	or	activation	activity	
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using	the	in	vitro	assays	in	this	study.		Taken	together,	the	de	novo	SAND	domain	
variants	likely	have	a	dominant‐negative	effect	(antimorph),	whereas	the	biallelic	
DEAF1	variants	lead	to	a	partial	loss‐of‐function	(hypomorph)	through	either	a	
reduction	in	function	with	normal	protein	levels	(missense	variants)	or	reduced	
protein	levels	due	to	NMD	(nonsense	and	frameshift	variants).	This	hypothesis	also	
explains	why	heterozygous	deletions	of	DEAF1	do	not	result	in	a	phenotype.		
The	phenotype	did	not	differ	significantly	between	patients	with	de	novo	and	
biallelic	DEAF1	variants,	except	for	the	presence	of	microcephaly	(p	<0.0001).	The	
latter	feature	was	present	in	three	out	of	the	five	patients	with	biallelic	variants.		
Patients	with	de	novo	or	biallelic	DEAF1	variants	had	DD/ID	with	severe	speech	
delay,	autism,	striking	mood	swings,	epilepsy,	gait	ataxia	or	other	walking	problems,	
a	high	pain	threshold,	sleep	disturbance,	brain	abnormalities,	and	extra‐neurologic	
manifestations,	such	as	recurrent	infections	and	gastrointestinal	abnormalities	that	
included	feeding	difficulties,	constipation,	and/or	diarrhea.	This	suggests	that	DAND	
consist	of	a	phenotypic	spectrum	of	features	centered	around	neurodevelopmental	
delay	rather	than	two	distinct	clinical	syndromes,	but	larger	number	of	patients	will	
be	required	to	confirm	this	hypothesis.	To	further	delineate	the	clinical	spectrum	
associated	with	de	mutations	in	DEAF1,	we	established		a	website	to	collect	detailed	
clinical	information	of	additional	individuals	to	be	identified	over	the	coming	years	
(http://humandiseasegenes.nl/deaf1/).	As	such,	the	clinical	picture	may	be	quite	
non‐specific.	Syndromes	to	be	included	in	DAND	differential	diagnosis	would	be	
Angelman	syndrome,	mostly	due	to	ID,	gait	abnormalities,	seizures,	paroxysmal	
bursts	of	laughter,	and	fascination	with	water,	and	Smith‐Magenis	syndrome,	in	
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particular	due	to	the	combination	of	ID	and	severe	sleeping	problems,15	and	Rett	
syndrome	for	the	biallelic	DEAF1	variants,	for	the	combination	of	microcephaly	and	
regression.		
The	exclusive	occurrence	of	microcephaly	and	an	increased	prevalence	of	
some	phenotypic	abnormalities,	such	as	movement	disorder	and	recurrent	
structural	brain	abnormalities,	in	patients	with	recessive	DEAF1	variants	may	also	
suggest	that	patients	with	recessive	DEAF1	variants	may	present	with	a	different	
and	somewhat	more	severe	clinical	condition	than	patients	with	de	novo	variants,	as	
these	variants	have	a	different	effect	on	a	molecular	level.	One	exception	to	the	
classical	DAND	phenotype	was	observed	in	one	patient	with	biallelic	DEAF1	variants	
as	he	has	preserved	cognitive	abilities.	Nevertheless,	this	patient	with	variants	
p.(Asp369Alafs*51)	and	p.(Cys540Metfs*18)	in	compound	heterozygosity	shared	
clinical	features	with	other	patients	with	biallelic	DEAF1	variants,	specifically	
inability	to	walk	or	to	speak,16,18‐20	movement	disorder,19	and	minor	brain	
abnormalities	including	corpus	callosum,	ventricles	and	white	matter	
abnormalities.18,20	Another	exception	to	the	classical	DAND	phenotype,	is	the	
occurrence	of	normal	speech	in	one	patient	with	the	de	novo	dominant	variant	
p.(Leu214Val),	who	manifests	ID,	showing	the	phenotypic	spectrum	is	wider	than	
previously	described.		
In	conclusion,	we	propose	that	different	variants	in	the	DEAF1	gene	result	in	
a	phenotypic	spectrum	centered	around	neurodevelopmental	delay.	A	pathogenic	de	
novo	dominant	variant	would	incapacitate	the	product	of	the	wild‐type	allele	and	
result	in	dominant‐negative	effect,	whereas	a	combination	of	two	recessive	variants	
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would	result	in	a	partial	loss‐of‐function.	Since	the	clinical	picture	can	be	quite	non‐
specific,	detailed	phenotype	information,	segregation	analysis,	and	functional	
analysis	are	fundamental	to	determine	the	pathogenicity	of	novel	variants	and	to	
improve	the	care	of	these	patients.		
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Figure	Legends	
Figure	1.	(a)	Structure	of	the	DEAF1	pre‐mRNA	[NM_021008.3]	with	light	blue	
boxes	indicating	the	5’and	3’	untranslated	regions	(UTRs)	and	dark	blue	boxes	
representing	the	coding	region	of	exons	1	to	12,	connected	by	lines	indicate	introns	
(not	drawn	to	scale).	(b)	Structure	of	DEAF1	protein	[NP_066288],	including	the	
DNA	binding	and	dimerization	SAND	domain,	the	zinc‐finger	homology	domain	
(ZnF)	also	involved	in	DNA	binding,	nuclear	localization	signal	(NLS),	nuclear	export	
signal	(NES),	and	MYND	domain.	Distribution	of	(c)	de	novo	heterozygous	variants	
leading	to	autosomal	dominant	mental	retardation	24	and	(d)	homozygous	or	
compound	heterozygous	variants	leading	to	autosomal	recessive	dyskinesia,	
seizures,	and	intellectual	developmental	disorder.	The	number	of	patients	described	
with	the	depicted	variant	are	indicated	between	parenthesis	if	the	variant	was	
indentified	in	more	than	one	case.	Novel	variants	are	indicated	in	bold.	(e)	Non‐
specific	facial	dysmorphisms	of	individuals	with	pathogenic	de	novo	DEAF1	variants	
(A	‐	L)	and	biallelic	DEAF1	variants	(M	‐	P),	showing	common	characteristics	as	
horizontal	eyebrow,	broad	nasal	tip,	exaggerated	cupid's	bow,	thick	lower	lip	
vermilion	and	pointed	chin:	(A)	Individual	with	p.(Gly212Ser),	at	20	years	old	
(AD/1);	(B)	Individual	with	p.(Thr213Pro),	at	7	years	old	(AD/3);	(C)	Individual	
p.(Leu214Val),	at	14	years	old	(AD/4);	(D)	Individual	with	p.(Leu214Pro),	at	3	years	
old	(AD/5);	(E)	Individual	with	p.(Lys216Glu),	at	10	years	old	(AD/6);	(F)	Individual	
with	p.(Lys216Asn),	at	7	years	old	(AD/7);	(G)	Individual	with	
p.(Pro174_Gly222del),	at	6	years	old	(AD/8);	(H)	Individual	with	p.(Gly225Glu),	at	5	
years	old	(AD/9);	(I)	Individual		with	p.(Ser236Gly),	at	4	years	old	(AD/11);	(J)	
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Individual	with	p.(Arg254del),	at	25	years	old	(AD/13);	(K)	Individual	with	
p.(Leu272Ser),	at	2	years	old	(AD/15);	(L)	Individual	with	p.(Ala276Pro),	at	14	
years	old	(AD/17);	(M)	Individual	with	p.(Asp369Alafs*51)	and	
p.(Cys540Metfs*18),	at	17	years	old	(AR/1);	(N)	Individual	with	p.(Trp234*)	and	
p.(Glu239Gly),	at	16	years	old	(AR/3);	(O)	Individual	with	p.(Arg224Gln)	in	
homozygosity,	at	10	years	old	(AR/4);	(P)	Individual	with	p.(Arg224Gln)	in	
homozygosity),	at	2	years	old	(AR/5).	Individuals	with	de	novo	variants	may	have	
high	forehead	and/or	macrocephaly,	while	individuals	with	biallelic	variants	may	
have	narrow	forehead	and	microcephaly.	
	
Figure	2.	The	de	novo	variant	c.664+1G>T	results	in	an	in‐frame	deletion	within	the	
DEAF1	SAND	domain.	(A)	Location	of	the	c.664+1G>T	variant	relative	to	exons	2‐5	
in	the	DEAF1	gene.	(B)	PCR	using	primers	that	would	amplify	exons	2‐5	of	DEAF1	
mRNA	(gray	bars	shown	in	A)	with	cDNA	from	control	or	c.664+1G>T	EBV‐LCL	
(individual	AD/8)	treated	with	vehicle	(‐)	or	CHX	(+).	A	single	DNA	band	was	
observed	in	control	EBV‐LCL	corresponding	to	correctly	spliced	DEAF1.		An	
additional,	approximately	150	basepairs	smaller,	PCR	product	was	identified	in	
c.664+1G>T	EBV‐LCL.	(C)	DNA	sequencing	indicated	c.664+1G>T	EBV‐LCL	have	
both	correctly	spliced	DEAF1	RNA	(above)	as	well	as	DEAF1	mRNA	that	lack	Exon4	
(below)	which	could	result	in	a	truncated	p.Pro174_Gly222del	DEAF1	protein.			(D)	
Lysates	from	HEK293t	cells	transfected	with	the	expression	constructs	for	WT	(~80	
kDa)	or	p.(Pro174_Gly222del)	variant	(~75	kDa)	were	separated	by	SDS‐PAGE	and	
analyzed	by	Western	blot	using	DEAF1	(red)	and	b‐ACTIN	(green)	antibodies.		(E)	
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Lysates	from	control	or	c.664+1G>T	EBV‐LCL	were	immunoprecipitated	with	
preimmune	serum	(PI)	or	DEAF1	antibodies	followed	by	Western	blots	with	DEAF1	
antibodies.	The	control	EBV‐LCL	shows	a	single	80	kDa	full	length	DEAF1	protein	
band.		An	additional	~75	kDa	DEAF1	protein	was	also	observed	in	the	EBV‐LCL	with	
the	c.664+1G>T	variant.		Closed	arrows	indicate	DEAF1	protein	bands	and	open	
arrow	indicates	heavy	chain	IgG	(IgG	HC).	
	
Figure	3.	Effect	of	DEAF1	variants	on	transcriptional	activity.	(A	and	B)	DEAF1	
promoter	activity	after	transfection	of	HEK293t	cells	with	WT	or	the	indicated	
variants.	(A)	Compared	to	WT,	all	de	novo	variants	resulted	in	loss	of	transcriptional	
repression	activity	at	the	DEAF1	promoter.	(B)	Heritable	biallelic	variants	had	no	
effect	on	DEAF1	promoter	transcriptional	repression,	except	for	p.(Trp234*).	(C	and	
D)	Eif4g3	promoter	activity	after	transfection	of	HEK293t	cells	with	WT	or	the	
indicated	variants.	(C)	All	de	novo	variants,	except	p.(Pro293Leu)	and	p.(Ser236Gly),	
resulted	in	suppression	of	transcription	relative	to	WT	transactivation.	No	change	
from	basal	promoter	activity	(pcDNA3)	was	detected	for	p.(Ser236Gly)	and	
increased	promoter	activity	was	observed	for	p.(Pro293Leu).	(D)	Heritable	biallelic	
variants	had	no	effect	on	Eif4g3	promoter	activation	compared	to	WT.	Each	bar	
represents	the	mean	+/‐	SEM	of	the	normalized	luciferase	activity	of	three	
independent	experiments	when	the	activity	of	pcDNA3	(DEAF1	promoter	alone)	
was	set	to	100%	(N=	5‐7	de	novo	variants	with	N=14‐15	WT,	N=4‐5	heritable	
variants	with	N=10‐12	WT).		**p<0.01	One‐way	ANOVA	with	Dunnett’s	multiple	
comparison	WT	DEAF1	versus	each	mutant.			
